Targeted microbubbles carrying lipid-oil-nanodroplets for ultrasound-triggered delivery of the hydrophobic drug, combretastatin A4
The hydrophobicity of a drug can be a major challenge in its development and prevents the clinical translation of highly potent anti-cancer agents. We have used a lipid-based nanoemulsion termed Lipid-Oil-Nanodroplets (LONDs) for the encapsulation and in vivo delivery of the poorly bioavailable comb...
Saved in:
Published in | Nanomedicine Vol. 36; p. 102401 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.08.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The hydrophobicity of a drug can be a major challenge in its development and prevents the clinical translation of highly potent anti-cancer agents. We have used a lipid-based nanoemulsion termed Lipid-Oil-Nanodroplets (LONDs) for the encapsulation and in vivo delivery of the poorly bioavailable combretastatin A4 (CA4). Drug delivery with CA4 LONDs was assessed in a xenograft model of colorectal cancer. LC–MS/MS analysis revealed that CA4 LONDs, administered at a drug dose four times lower than drug control, achieved equivalent concentrations of CA4 intratumorally. We then attached CA4 LONDs to microbubbles (MBs) and targeted this construct to VEGFR2. A reduction in tumor perfusion was observed in CA4 LONDs-MBs treated tumors. A combination study with irinotecan demonstrated a greater reduction in tumor growth and perfusion (P = 0.01) compared to irinotecan alone. This study suggests that LONDs, either alone or attached to targeted MBs, have the potential to significantly enhance tumor-specific hydrophobic drug delivery.
A number of highly potent and promising drugs fail to reach the clinic due to poor-water solubility. Lipid-stabilized Oil Nanodroplets (LONDs) were produced specifically for the encapsulation of poorly-water soluble drugs such as the vascular disruptive agent Combretastatin A4 (CA4). Initial pre-clinical work with CA4 LONDs showed an accumulation of CA4 in tumor tissue. Attachment of CA4 LONDs to VEGFR2-targeted Microbubbles (MBs) permitted the controlled and ultrasound triggered release of CA4 in tumors, confirmed by a reduction in tumor perfusion post-treatment. The combination of low dose irinotecan with CA4 LONDs-MBs further enhanced the anti-tumor effects of both compounds [Display omitted] |
---|---|
AbstractList | The hydrophobicity of a drug can be a major challenge in its development and prevents the clinical translation of highly potent anti-cancer agents. We have used a lipid-based nanoemulsion termed Lipid-Oil-Nanodroplets (LONDs) for the encapsulation and in vivo delivery of the poorly bioavailable combretastatin A4 (CA4). Drug delivery with CA4 LONDs was assessed in a xenograft model of colorectal cancer. LC-MS/MS analysis revealed that CA4 LONDs, administered at a drug dose four times lower than drug control, achieved equivalent concentrations of CA4 intratumorally. We then attached CA4 LONDs to microbubbles (MBs) and targeted this construct to VEGFR2. A reduction in tumor perfusion was observed in CA4 LONDs-MBs treated tumors. A combination study with irinotecan demonstrated a greater reduction in tumor growth and perfusion (P = 0.01) compared to irinotecan alone. This study suggests that LONDs, either alone or attached to targeted MBs, have the potential to significantly enhance tumor-specific hydrophobic drug delivery. The hydrophobicity of a drug can be a major challenge in its development and prevents the clinical translation of highly potent anti-cancer agents. We have used a lipid-based nanoemulsion termed Lipid-Oil-Nanodroplets (LONDs) for the encapsulation and in vivo delivery of the poorly bioavailable combretastatin A4 (CA4). Drug delivery with CA4 LONDs was assessed in a xenograft model of colorectal cancer. LC–MS/MS analysis revealed that CA4 LONDs, administered at a drug dose four times lower than drug control, achieved equivalent concentrations of CA4 intratumorally. We then attached CA4 LONDs to microbubbles (MBs) and targeted this construct to VEGFR2. A reduction in tumor perfusion was observed in CA4 LONDs-MBs treated tumors. A combination study with irinotecan demonstrated a greater reduction in tumor growth and perfusion (P = 0.01) compared to irinotecan alone. This study suggests that LONDs, either alone or attached to targeted MBs, have the potential to significantly enhance tumor-specific hydrophobic drug delivery. A number of highly potent and promising drugs fail to reach the clinic due to poor-water solubility. Lipid-stabilized Oil Nanodroplets (LONDs) were produced specifically for the encapsulation of poorly-water soluble drugs such as the vascular disruptive agent Combretastatin A4 (CA4). Initial pre-clinical work with CA4 LONDs showed an accumulation of CA4 in tumor tissue. Attachment of CA4 LONDs to VEGFR2-targeted Microbubbles (MBs) permitted the controlled and ultrasound triggered release of CA4 in tumors, confirmed by a reduction in tumor perfusion post-treatment. The combination of low dose irinotecan with CA4 LONDs-MBs further enhanced the anti-tumor effects of both compounds [Display omitted] |
ArticleNumber | 102401 |
Author | McVeigh, Laura E. Evans, Stephen D. Coletta, P. Louise Bushby, Richard J. Mico, Victoria Charalambous, Antonia Ingram, Nicola McLaughlan, James R. Volpato, Milène Peyman, Sally A. Wierzbicki, Antonia Markham, Alexander F. Loadman, Paul M. Marston, Gemma |
Author_xml | – sequence: 1 givenname: Antonia surname: Charalambous fullname: Charalambous, Antonia organization: Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James's University. Hospital, Leeds, United Kingdom – sequence: 2 givenname: Victoria surname: Mico fullname: Mico, Victoria organization: Molecular and Nanoscale Physics Group, School of Physics and Astronomy, University of Leeds, Leeds, United Kingdom – sequence: 3 givenname: Laura E. surname: McVeigh fullname: McVeigh, Laura E. organization: Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James's University. Hospital, Leeds, United Kingdom – sequence: 4 givenname: Gemma surname: Marston fullname: Marston, Gemma organization: Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James's University. Hospital, Leeds, United Kingdom – sequence: 5 givenname: Nicola surname: Ingram fullname: Ingram, Nicola organization: Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James's University. Hospital, Leeds, United Kingdom – sequence: 6 givenname: Milène surname: Volpato fullname: Volpato, Milène organization: Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James's University. Hospital, Leeds, United Kingdom – sequence: 7 givenname: Sally A. surname: Peyman fullname: Peyman, Sally A. organization: Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James's University. Hospital, Leeds, United Kingdom – sequence: 8 givenname: James R. surname: McLaughlan fullname: McLaughlan, James R. organization: School of Electronic and Electrical Engineering, University of Leeds, United Kingdom – sequence: 9 givenname: Antonia surname: Wierzbicki fullname: Wierzbicki, Antonia organization: Institute of Cancer Therapeutics, University of Bradford, Bradford, United Kingdom – sequence: 10 givenname: Paul M. surname: Loadman fullname: Loadman, Paul M. organization: Institute of Cancer Therapeutics, University of Bradford, Bradford, United Kingdom – sequence: 11 givenname: Richard J. surname: Bushby fullname: Bushby, Richard J. organization: Molecular and Nanoscale Physics Group, School of Physics and Astronomy, University of Leeds, Leeds, United Kingdom – sequence: 12 givenname: Alexander F. surname: Markham fullname: Markham, Alexander F. organization: Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James's University. Hospital, Leeds, United Kingdom – sequence: 13 givenname: Stephen D. surname: Evans fullname: Evans, Stephen D. organization: Molecular and Nanoscale Physics Group, School of Physics and Astronomy, University of Leeds, Leeds, United Kingdom – sequence: 14 givenname: P. Louise surname: Coletta fullname: Coletta, P. Louise email: P.L.Coletta@leeds.ac.uk organization: Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James's University. Hospital, Leeds, United Kingdom |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33894396$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kDtrHDEURkVwiB_JH0gRVKbIbCSN5iFIY0xeYEjj1EKPq1ktGmkjaQzb-pdnhnVcptJFnO-73HONLmKKgNB7SnaU0P7zYRdVTDtGGF0_GCf0FbqiHReN6Dm7eJlbfomuSzkQ0g6EiDfosm1HwVvRX6GnB5UnqGDx7E1OetE6QMFG5XzyccLBH71tkg_NtsvmdAxQC3Yp4yXUrEpaom1q9tMEeW2xEPwj5BNODtc94P1py-yT9gbbvEyfsEmzzlBVqar6iG_5W_TaqVDg3fN7g35_-_pw96O5__X9593tfWM4IbWhHLgY-SAIIQwUHZgZtKNjr90wtNy4XrGuM0wNrrdUMDX2rXFAe9GNnSa6vUEfz73HnP4sUKqcfTEQgoqQliJZR0fWEkrEirIzuiopJYOTx-xnlU-SErm5lwe5-ZCbe3l2v4Y-PPcvegb7EvknewW-nAFYr3z0kGUxHqIB6zOYKm3y_-v_C4ZamWM |
CitedBy_id | crossref_primary_10_1080_17425247_2022_2110585 crossref_primary_10_1021_acs_molpharmaceut_3c00921 crossref_primary_10_3390_pharmaceutics15061625 crossref_primary_10_1080_17425247_2022_2061459 crossref_primary_10_1021_acs_jpcb_2c07256 crossref_primary_10_1021_acs_langmuir_2c02303 crossref_primary_10_1063_5_0040213 |
Cites_doi | 10.1002/ijc.10655 10.1158/1078-0432.CCR-0364-3 10.1038/nrc1628 10.1118/1.4808149 10.1161/01.CIR.98.1.1 10.1016/j.ejps.2017.09.041 10.1016/j.ijrobp.2006.12.051 10.1016/j.ejca.2005.01.001 10.1158/1078-0432.CCR-11-3376 10.1039/c2lc40634a 10.1016/j.ijpharm.2014.09.055 10.1016/j.ultrasmedbio.2006.03.017 10.1021/np50057a011 10.1016/j.addr.2013.11.009 10.1080/09553000010007695 10.1158/0008-5472.CAN-14-0572 10.1038/nrc1369 10.3892/etm.2011.253 10.1208/pt070232 10.1016/j.chempr.2016.12.005 10.2147/IJN.S188971 10.1021/mp400081b 10.1016/j.mvr.2006.01.004 10.1016/j.ijrobp.2005.03.009 10.1016/j.ctrv.2010.05.001 10.1080/10611860400011935 10.1007/BF01954881 10.1089/thy.2008.0321 10.1016/j.ejphar.2009.08.020 10.1016/j.ijpharm.2017.05.009 10.1016/j.ejca.2003.09.006 10.1016/j.apsb.2015.07.003 10.1102/1470-7330.2007.0031 10.1038/sj.bjc.6692174 10.1054/bjoc.2000.1361 10.7150/thno.49670 10.1200/JCO.2016.70.8594 10.1016/j.ejpb.2010.01.002 10.1007/s11095-012-0797-2 10.1016/j.ygyno.2017.01.031 10.1016/j.biomaterials.2013.05.081 10.1016/j.ultras.2008.04.009 10.1038/s41598-019-46410-6 10.1038/s41563-019-0566-2 10.1039/b823051j 10.1021/jm00010a011 10.1016/S0360-3016(02)03924-X 10.1186/1471-2407-12-522 10.1097/00001813-200101000-00008 10.1016/j.ultrasmedbio.2017.12.002 10.1016/j.ultrasmedbio.2011.12.011 10.18632/oncotarget.6999 10.1016/j.addr.2013.11.008 10.1172/JCI24586 |
ContentType | Journal Article |
Copyright | 2021 The Authors Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2021 The Authors – notice: Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved. |
DBID | 6I. AAFTH CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.nano.2021.102401 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1549-9642 |
EndPage | 102401 |
ExternalDocumentID | 10_1016_j_nano_2021_102401 33894396 S1549963421000447 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Medical Research Council grantid: MC_PC_14109 – fundername: Medical Research Council grantid: MR/L01629X |
GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1~. 1~5 4.4 457 4G. 53G 5VS 6I. 7-5 71M 8P~ AAAJQ AABXZ AACTN AAEDT AAEDW AAEPC AAFTH AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATCM AAXUO ABBQC ABGSF ABLVK ABMAC ABMZM ABUDA ABXDB ABXRA ABYKQ ABZDS ACDAQ ACGFS ACNNM ACRLP ADBBV ADEZE ADMUD ADTZH ADUVX AEBSH AECPX AEHWI AEKER AEVXI AEZYN AFKWA AFRHN AFRZQ AFTJW AFXIZ AGEKW AGHFR AGUBO AGYEJ AHJVU AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR BJAXD BKOJK BLXMC BNPGV CJTIS CS3 DOVZS EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W JJJVA KOM LCYCR LUGTX M41 MAGPM MO0 N9A O-L O9- OAUVE OD~ OGGZJ OO0 OZT P-8 P-9 P2P PC. Q38 RIG ROL RPZ SDF SDG SEL SES SEW SPC SSH SSI SSM SSP SST SSU SSZ T5K Z5R ~G- AAXKI AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX ACRPL ADNMO CITATION 7X8 |
ID | FETCH-LOGICAL-c400t-14e4984790002ea172c7bf186bf7734cf6a255c2a7f6d192a863cfe169585b0b3 |
IEDL.DBID | AIKHN |
ISSN | 1549-9634 |
IngestDate | Wed Dec 04 03:05:30 EST 2024 Fri Dec 06 01:01:50 EST 2024 Sat Sep 28 08:20:42 EDT 2024 Fri Feb 23 02:43:42 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | LOD VEGFR2 Combretastatin A4 Targeting Tx CA4P EPR Ultrasound trigger i.p ICAM-1 CA4G LONDs i.v Lipid-Oil-Nanodroplets (LONDs) VDA CRC CA4 TGI Microbubbles CEPs US 5-FU MBs |
Language | English |
License | This is an open access article under the CC BY license. Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c400t-14e4984790002ea172c7bf186bf7734cf6a255c2a7f6d192a863cfe169585b0b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S1549963421000447 |
PMID | 33894396 |
PQID | 2518230109 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | proquest_miscellaneous_2518230109 crossref_primary_10_1016_j_nano_2021_102401 pubmed_primary_33894396 elsevier_sciencedirect_doi_10_1016_j_nano_2021_102401 |
PublicationCentury | 2000 |
PublicationDate | August 2021 2021-08-00 20210801 |
PublicationDateYYYYMMDD | 2021-08-01 |
PublicationDate_xml | – month: 08 year: 2021 text: August 2021 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Nanomedicine |
PublicationTitleAlternate | Nanomedicine |
PublicationYear | 2021 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Chaplin, Hill (bb0190) 2002; 54 Cooney, Radivoyevitch, Dowlati, Overmoyer, Levitan, Robertson (bb0065) 2004; 10 Jiang, Li, Tian, Pan, Xu, Zhang (bb0075) 2019; 14 Chase, Chaplin, Monk (bb0010) 2017; 145 Malcontenti-Wilson, Muralidharan, Skinner, Christophi, Sherris, O’Brien (bb0270) 2001; 7 Nabha, Mohammad, Wall, Dutcher, Salkini, Pettit (bb0275) 2001; 12 Gaspari, Prota, Bargsten, Cavalli, Steinmetz (bb0045) 2017; 2 Su, Long, Deng, Feng, Zhang, Chen (bb0255) 2014; 476 Nguyen, Fifis, Malcontenti-Wilson, Chan, Costa, Nikfarjam (bb0290) 2012; 12 Wang, Mongayt, Torchilin (bb0080) 2005; 13 Nallamothu, Wood, Pattillo, Scott, Kiani, Moore (bb0240) 2006; 7 Mooney, Nagaiah, Fu, Wasman, Cooney, Savvides (bb0070) 2009; 19 Escoffre, Novell, Serrière, Lecomte, Bouakaz (bb0235) 2013; 10 Fang, Hung, Hua, Hwang (bb0085) 2009; 49 Wang, Chen, Liu, Wu, Zhou, Wang (bb0265) 2013; 34 Chen, Gong, Zhao, Fu, Zhang, Gong (bb0090) 2018; 111 Lentacker, De Cock, Deckers, De Smedt, Moonen (bb0135) 2014; 72 Liang, Ni, Chen (bb0195) 2016; 7 Villanueva, Jankowski, Klibanov, Pina, Alber, Watkins (bb0125) 1998; 98 Nathan, Zweifel, Padhani, Koh, Ng, Collins (bb0305) 2012; 18 Chaplin, Pettit, Hill (bb0050) 1996; 74 Pettit, Singh, Schmidt, Niven, Hamel, Lin (bb0035) 1988; 51 Cullis, Kalber, Ashton, Cartwright, Griffiths, Ryan (bb0170) 2006; 71 El-Emir, Boxer, Petrie, Boden, Dearling, Begent (bb0015) 2005; 41 Peyman SA, Abou-Saleh RH, McLaughlan JR, Ingram N, Johnson BRG, Critchley K, et al. Expanding 3D geometry for enhanced on-chip microbubble production and single step formation of liposome modified microbubbles. Lab Chip 2012;12:4544–4522. Kerbel, Kamen (bb0210) 2004; 4 Wildiers, Ahmed, Guetens, De Boeck, de Bruijn, Landuyt (bb0295) 2004; 40 Seiler, Ziemer, Schultz, Lee, Sehgal (bb0025) 2007; 7 Mico, Charalambous, Peyman, Abou-Saleh, Markham, Coletta (bb0140) 2017; 526 National Center for Biotechnology Information. Glyceryl tripropanoate. PubChem Compd Database 2005. Pettit, Singh, Hamel, Lin, Alberts, Garcia-Kendal (bb0040) 1989; 45 (accessed April 24, 2018). Grosios, Loadman, Swaine, Pettit, Bibby (bb0220) 2000; 20 Kalra, Kim, Klinz, Paz, Cain, Drummond (bb0175) 2014; 74 Vincent, Kermani, Young, Cheng, Zhang, Shido (bb0225) 2005; 115 Bertrand, Wu, Xu, Kamaly, Farokhzad (bb0095) 2014; 66 Mico (bb0155) 2017 Hill, Chaplin, Lewis, Tozer (bb0205) 2002; 102 Nallamothu, Wood, Kiani, Moore, Horton, Thoma (bb0260) 2006; 60 Kotopoulis S, Dimcevski G, Gilja OH, Hoem D, Postema M. Treatment of human pancreatic cancer using combined ultrasound, microbubbles, and gemcitabine: a clinical case study. Med Phys 2013;40:072902–1–072902–9. Zhang, Wang, Bian, Zhang, Zhang (bb0245) 2010; 74 Dai, Jin, Zhang, Wang, Wang, Zhang (bb0250) 2012; 29 Pettit GR, Singh SB, Boyd MR, Hamel E, Pettit RK, Schmidt JM, et al. Antineoplastic agents .291. Isolation and synthesis of combretastatin A-4, A-5 and A-6. J Med Chem 1995;38:1666–72. Tartis, McCallan, Lum, LaBell, Stieger, Matsunaga TO (bb0120) 2006; 32 Abdelrahman, Marston, Hull, Markham, Jones, Evans (bb0160) 2012; 38 Kalepu, Nekkanti (bb0005) 2015; 5 Zhao, Jiang, Hahn, Mason (bb0020) 2005; 62 McVeigh, Wijetunga, Ingram, Marston, Prasad, Markham (bb0165) 2019; 9 Sindhwani, Syed, Ngai, Kingston, Maiorino, Rothschild (bb0100) 2020; 19 Willmann, Bonomo, Testa, Rinaldi, Rindi, Valluru (bb0115) 2017; 35 Murata, Overgaard, Horsman (bb0180) 2001; 77 Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829–34. Murakami, Ogata, Akagi, Ishibashi, Shirouzu (bb0300) 2011; 2 Salmon, Siemann (bb0280) 2007; 68 Zhang, Chen, Liu, Yang, Lv, Wang (bb0285) 2018; 44 Fioravanti, Canu, Alì, Orlandi, Allegrini, Di Desidero (bb0200) 2009; 619 Tozer, Kanthou, Baguley (bb0030) 2005; 5 Grosios, Holwell, McGown, Pettit, Bibby (bb0055) 1999; 81 Lentacker, De Smedt, Sanders (bb0110) 2009; 5 Siemann (bb0230) 2011; 37 Parkins CS, Holder a L, Hill SA, Chaplin DJ, Tozer GM. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer 2000;83:811–6. Ingram, Mcveigh, Abou-saleh, Maynard, Peyman, McLaughlan (bb0130) 2020; 10 Wildiers (10.1016/j.nano.2021.102401_bb0295) 2004; 40 Zhao (10.1016/j.nano.2021.102401_bb0020) 2005; 62 Liang (10.1016/j.nano.2021.102401_bb0195) 2016; 7 Tozer (10.1016/j.nano.2021.102401_bb0030) 2005; 5 Fioravanti (10.1016/j.nano.2021.102401_bb0200) 2009; 619 Lentacker (10.1016/j.nano.2021.102401_bb0135) 2014; 72 Zhang (10.1016/j.nano.2021.102401_bb0245) 2010; 74 Zhang (10.1016/j.nano.2021.102401_bb0285) 2018; 44 Ingram (10.1016/j.nano.2021.102401_bb0130) 2020; 10 Su (10.1016/j.nano.2021.102401_bb0255) 2014; 476 Kerbel (10.1016/j.nano.2021.102401_bb0210) 2004; 4 Pettit (10.1016/j.nano.2021.102401_bb0035) 1988; 51 10.1016/j.nano.2021.102401_bb0185 Murakami (10.1016/j.nano.2021.102401_bb0300) 2011; 2 Nallamothu (10.1016/j.nano.2021.102401_bb0260) 2006; 60 10.1016/j.nano.2021.102401_bb0060 Willmann (10.1016/j.nano.2021.102401_bb0115) 2017; 35 10.1016/j.nano.2021.102401_bb0105 Escoffre (10.1016/j.nano.2021.102401_bb0235) 2013; 10 Murata (10.1016/j.nano.2021.102401_bb0180) 2001; 77 Chase (10.1016/j.nano.2021.102401_bb0010) 2017; 145 Chen (10.1016/j.nano.2021.102401_bb0090) 2018; 111 Wang (10.1016/j.nano.2021.102401_bb0265) 2013; 34 10.1016/j.nano.2021.102401_bb0145 Wang (10.1016/j.nano.2021.102401_bb0080) 2005; 13 Dai (10.1016/j.nano.2021.102401_bb0250) 2012; 29 Lentacker (10.1016/j.nano.2021.102401_bb0110) 2009; 5 Cooney (10.1016/j.nano.2021.102401_bb0065) 2004; 10 Mico (10.1016/j.nano.2021.102401_bb0140) 2017; 526 Gaspari (10.1016/j.nano.2021.102401_bb0045) 2017; 2 Abdelrahman (10.1016/j.nano.2021.102401_bb0160) 2012; 38 Mico (10.1016/j.nano.2021.102401_bb0155) 2017 Grosios (10.1016/j.nano.2021.102401_bb0220) 2000; 20 Seiler (10.1016/j.nano.2021.102401_bb0025) 2007; 7 Siemann (10.1016/j.nano.2021.102401_bb0230) 2011; 37 Jiang (10.1016/j.nano.2021.102401_bb0075) 2019; 14 Chaplin (10.1016/j.nano.2021.102401_bb0050) 1996; 74 10.1016/j.nano.2021.102401_bb0215 Sindhwani (10.1016/j.nano.2021.102401_bb0100) 2020; 19 El-Emir (10.1016/j.nano.2021.102401_bb0015) 2005; 41 Kalepu (10.1016/j.nano.2021.102401_bb0005) 2015; 5 Tartis (10.1016/j.nano.2021.102401_bb0120) 2006; 32 Cullis (10.1016/j.nano.2021.102401_bb0170) 2006; 71 Hill (10.1016/j.nano.2021.102401_bb0205) 2002; 102 Kalra (10.1016/j.nano.2021.102401_bb0175) 2014; 74 Nguyen (10.1016/j.nano.2021.102401_bb0290) 2012; 12 Pettit (10.1016/j.nano.2021.102401_bb0040) 1989; 45 Nathan (10.1016/j.nano.2021.102401_bb0305) 2012; 18 Mooney (10.1016/j.nano.2021.102401_bb0070) 2009; 19 Villanueva (10.1016/j.nano.2021.102401_bb0125) 1998; 98 Bertrand (10.1016/j.nano.2021.102401_bb0095) 2014; 66 Nabha (10.1016/j.nano.2021.102401_bb0275) 2001; 12 Salmon (10.1016/j.nano.2021.102401_bb0280) 2007; 68 Vincent (10.1016/j.nano.2021.102401_bb0225) 2005; 115 Fang (10.1016/j.nano.2021.102401_bb0085) 2009; 49 Grosios (10.1016/j.nano.2021.102401_bb0055) 1999; 81 Nallamothu (10.1016/j.nano.2021.102401_bb0240) 2006; 7 10.1016/j.nano.2021.102401_bb0150 Chaplin (10.1016/j.nano.2021.102401_bb0190) 2002; 54 McVeigh (10.1016/j.nano.2021.102401_bb0165) 2019; 9 Malcontenti-Wilson (10.1016/j.nano.2021.102401_bb0270) 2001; 7 |
References_xml | – volume: 41 start-page: 799 year: 2005 end-page: 806 ident: bb0015 article-title: Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice publication-title: Eur J Cancer contributor: fullname: Begent – volume: 14 start-page: 1789 year: 2019 end-page: 1804 ident: bb0075 article-title: Liver-targeted liposomes for codelivery of curcumin and combretastatin A4 phosphate: preparation, characterization, and antitumor effects publication-title: Int J Nanomedicine contributor: fullname: Zhang – volume: 9 start-page: 1 year: 2019 end-page: 9 ident: bb0165 article-title: Development of orthotopic tumour models using ultrasound-guided intrahepatic injection publication-title: Sci Rep contributor: fullname: Markham – volume: 4 start-page: 423 year: 2004 end-page: 436 ident: bb0210 article-title: The anti-angiogenic basis of metronomic chemotherapy publication-title: Nat Rev Cancer contributor: fullname: Kamen – volume: 7 start-page: E1 year: 2006 end-page: 10 ident: bb0240 article-title: A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation publication-title: AAPS PharmSciTech contributor: fullname: Moore – volume: 98 start-page: 1 year: 1998 end-page: 5 ident: bb0125 article-title: Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells publication-title: Circulation contributor: fullname: Watkins – volume: 5 start-page: 2161 year: 2009 end-page: 2170 ident: bb0110 article-title: Drug loaded microbubble design for ultrasound triggered delivery publication-title: Soft Matter contributor: fullname: Sanders – volume: 77 start-page: 195 year: 2001 end-page: 204 ident: bb0180 article-title: Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues publication-title: Int J Radiat Biol contributor: fullname: Horsman – volume: 145 start-page: 393 year: 2017 end-page: 406 ident: bb0010 article-title: The development and use of vascular targeted therapy in ovarian cancer publication-title: Gynecol Oncol contributor: fullname: Monk – volume: 19 start-page: 233 year: 2009 end-page: 240 ident: bb0070 article-title: A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome publication-title: Thyroid contributor: fullname: Savvides – volume: 37 start-page: 63 year: 2011 end-page: 74 ident: bb0230 article-title: The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents publication-title: Cancer Tretment Rev contributor: fullname: Siemann – volume: 13 start-page: 73 year: 2005 end-page: 80 ident: bb0080 article-title: Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugated and positively charged lipids publication-title: J Drug Target contributor: fullname: Torchilin – volume: 7 start-page: 1052 year: 2001 end-page: 1060 ident: bb0270 article-title: Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model publication-title: Clin Cancer Res contributor: fullname: O’Brien – volume: 19 start-page: 566 year: 2020 end-page: 575 ident: bb0100 article-title: The entry of nanoparticles into solid tumours publication-title: Nat Mater contributor: fullname: Rothschild – volume: 74 start-page: 7003 year: 2014 end-page: 7013 ident: bb0175 article-title: Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion publication-title: Cancer Res contributor: fullname: Drummond – volume: 115 start-page: 2992 year: 2005 end-page: 3006 ident: bb0225 article-title: Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling publication-title: J Clin Invest contributor: fullname: Shido – volume: 5 start-page: 423 year: 2005 end-page: 435 ident: bb0030 article-title: Disrupting tumour blood vessels publication-title: Nat Rev Cancer contributor: fullname: Baguley – volume: 476 start-page: 241 year: 2014 end-page: 252 ident: bb0255 article-title: Construction of a two-in-one liposomal system (TWOLips) for tumor-targeted combination therapy publication-title: Int J Pharm contributor: fullname: Chen – volume: 66 start-page: 2 year: 2014 end-page: 25 ident: bb0095 article-title: Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology publication-title: Adv Drug Deliv Rev contributor: fullname: Farokhzad – volume: 2 start-page: 595 year: 2011 end-page: 600 ident: bb0300 article-title: Circulating endothelial progenitor cells in metronomic chemotherapy using irinotecan and/or bevacizumab for colon carcinoma: study of their clinical significance publication-title: Exp Ther Med contributor: fullname: Shirouzu – volume: 5 start-page: 442 year: 2015 end-page: 453 ident: bb0005 article-title: Insoluble drug delivery strategies: review of recent advances and business prospects publication-title: Acta Pharm Sin B contributor: fullname: Nekkanti – volume: 32 start-page: 1771 year: 2006 end-page: 1780 ident: bb0120 article-title: Therapeutic effects of paclitaxel-containing ultrasound contrast agents publication-title: Ultrasound Med Biol contributor: fullname: Matsunaga TO – volume: 12 start-page: 57 year: 2001 end-page: 63 ident: bb0275 article-title: Evaluation of combretastatin A-4 prodrug in a non-Hodgkin’s lymphoma xenograft model: preclinical efficacy publication-title: Anticancer Drugs contributor: fullname: Pettit – volume: 51 start-page: 517 year: 1988 end-page: 527 ident: bb0035 article-title: Isolation, structure, synthesis, and antimitotic properties of combretastatins B-3 and B-4 from Combretum caffrum publication-title: J Nat Prod contributor: fullname: Lin – volume: 74 start-page: 467 year: 2010 end-page: 473 ident: bb0245 article-title: Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy : in vitro and in vivo studies publication-title: Eur J Pharm Biopharm contributor: fullname: Zhang – volume: 74 start-page: S86 year: 1996 end-page: S88 ident: bb0050 article-title: Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate publication-title: Br J Cancer contributor: fullname: Hill – volume: 49 start-page: 39 year: 2009 end-page: 46 ident: bb0085 article-title: Acoustically active perfluorocarbon nanoemulsions as drug delivery carriers for camptothecin: drug release and cytotoxicity against cancer cells publication-title: Ultrasonics contributor: fullname: Hwang – volume: 10 start-page: 96 year: 2004 end-page: 100 ident: bb0065 article-title: Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer publication-title: Clin Cancer Res contributor: fullname: Robertson – year: 2017 ident: bb0155 article-title: Developing microbubble-nanodroplet composites for enhanced hydrophobic drug delivery contributor: fullname: Mico – volume: 10 start-page: 10973 year: 2020 end-page: 10992 ident: bb0130 article-title: Ultrasound-triggered therapeutic microbubbles enhance the efficacy of cytotoxic drugs by increasing circulation and tumor drug accumulation and limiting bioavailability and toxicity in normal tissues publication-title: Theranostics contributor: fullname: McLaughlan – volume: 526 start-page: 547 year: 2017 end-page: 555 ident: bb0140 article-title: Evaluation of lipid-stabilised tripropionin nanodroplets as a delivery route for combretastatin A4 publication-title: Int J Pharm contributor: fullname: Coletta – volume: 29 start-page: 2902 year: 2012 end-page: 2911 ident: bb0250 article-title: Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes publication-title: Pharm Res contributor: fullname: Zhang – volume: 60 start-page: 144 year: 2006 end-page: 155 ident: bb0260 article-title: A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies publication-title: PDA J Pharm Sci Technol contributor: fullname: Thoma – volume: 10 start-page: 2667 year: 2013 end-page: 2675 ident: bb0235 article-title: Irinotecan delivery by microbubble-assisted ultrasound: in vitro validation and a pilot preclinical study publication-title: Mol Pharm contributor: fullname: Bouakaz – volume: 38 start-page: 432 year: 2012 end-page: 442 ident: bb0160 article-title: High-frequency ultrasound for in vivo measurement of colon wall thickness in mice publication-title: Ultrasound Med Biol contributor: fullname: Evans – volume: 20 start-page: 229 year: 2000 end-page: 234 ident: bb0220 article-title: Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma publication-title: Anticancer Res contributor: fullname: Bibby – volume: 12 start-page: 1 year: 2012 end-page: 13 ident: bb0290 article-title: Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments publication-title: BMC Cancer contributor: fullname: Nikfarjam – volume: 44 start-page: 840 year: 2018 end-page: 852 ident: bb0285 article-title: Quantitative evaluation of combretastatin A4 phosphate early efficacy in a tumor model with dynamic contrast-enhanced ultrasound publication-title: Ultrasound Med Biol contributor: fullname: Wang – volume: 72 start-page: 49 year: 2014 end-page: 64 ident: bb0135 article-title: Understanding ultrasound induced sonoporation: definitions and underlying mechanisms publication-title: Adv Drug Deliv Rev contributor: fullname: Moonen – volume: 7 start-page: 216 year: 2007 end-page: 223 ident: bb0025 article-title: Dose-response relationship of ultrasound contrast agent in an in vivo murine melanoma model publication-title: Cancer Imaging contributor: fullname: Sehgal – volume: 40 start-page: 284 year: 2004 end-page: 290 ident: bb0295 article-title: Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence publication-title: Eur J Cancer contributor: fullname: Landuyt – volume: 102 start-page: 70 year: 2002 end-page: 74 ident: bb0205 article-title: Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models publication-title: Int J Cancer contributor: fullname: Tozer – volume: 34 start-page: 7181 year: 2013 end-page: 7190 ident: bb0265 article-title: pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma publication-title: Biomaterials contributor: fullname: Wang – volume: 2 start-page: 102 year: 2017 end-page: 113 ident: bb0045 article-title: Structural basis of cis- and trans-combretastatin binding to tubulin publication-title: Chem contributor: fullname: Steinmetz – volume: 81 start-page: 1318 year: 1999 end-page: 1327 ident: bb0055 article-title: In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug publication-title: Br J Cancer contributor: fullname: Bibby – volume: 62 start-page: 872 year: 2005 end-page: 880 ident: bb0020 article-title: Tumor physiologic response to combretastatin A4 phosphate assessed by MRI publication-title: Int J Radiat Oncol Biol Phys contributor: fullname: Mason – volume: 45 start-page: 209 year: 1989 end-page: 211 ident: bb0040 article-title: Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 publication-title: Experientia contributor: fullname: Garcia-Kendal – volume: 18 start-page: 3428 year: 2012 end-page: 3439 ident: bb0305 article-title: Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer publication-title: Clin Cancer Res contributor: fullname: Collins – volume: 619 start-page: 8 year: 2009 end-page: 14 ident: bb0200 article-title: Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer publication-title: Eur J Pharmacol contributor: fullname: Di Desidero – volume: 71 start-page: 76 year: 2006 end-page: 84 ident: bb0170 article-title: Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126 publication-title: Microvasc Res contributor: fullname: Ryan – volume: 111 start-page: 293 year: 2018 end-page: 302 ident: bb0090 article-title: A comparison study between lycobetaine-loaded nanoemulsion and liposome using nRGD as therapeutic adjuvant for lung cancer therapy publication-title: Eur J Pharm Sci contributor: fullname: Gong – volume: 54 start-page: 1491 year: 2002 end-page: 1496 ident: bb0190 article-title: The development of combretastatin A4 phosphate as a vascular targeting agent publication-title: Int J Radiat Oncol Biol Phys contributor: fullname: Hill – volume: 68 start-page: 211 year: 2007 end-page: 217 ident: bb0280 article-title: Characterizing the tumor response to treatment with combretastatin A4 phosphate publication-title: Int J Radiat Oncol Biol Phys contributor: fullname: Siemann – volume: 35 start-page: 2133 year: 2017 end-page: 2140 ident: bb0115 article-title: Ultrasound molecular imaging with BR55 in patients with breast & ovarian lesions: first-in-human results publication-title: J Clin Oncol contributor: fullname: Valluru – volume: 7 start-page: 15444 year: 2016 end-page: 15459 ident: bb0195 article-title: Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions publication-title: Oncotarget contributor: fullname: Chen – volume: 102 start-page: 70 year: 2002 ident: 10.1016/j.nano.2021.102401_bb0205 article-title: Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models publication-title: Int J Cancer doi: 10.1002/ijc.10655 contributor: fullname: Hill – volume: 10 start-page: 96 year: 2004 ident: 10.1016/j.nano.2021.102401_bb0065 article-title: Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-0364-3 contributor: fullname: Cooney – volume: 5 start-page: 423 year: 2005 ident: 10.1016/j.nano.2021.102401_bb0030 article-title: Disrupting tumour blood vessels publication-title: Nat Rev Cancer doi: 10.1038/nrc1628 contributor: fullname: Tozer – ident: 10.1016/j.nano.2021.102401_bb0105 doi: 10.1118/1.4808149 – volume: 98 start-page: 1 year: 1998 ident: 10.1016/j.nano.2021.102401_bb0125 article-title: Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells publication-title: Circulation doi: 10.1161/01.CIR.98.1.1 contributor: fullname: Villanueva – volume: 111 start-page: 293 year: 2018 ident: 10.1016/j.nano.2021.102401_bb0090 article-title: A comparison study between lycobetaine-loaded nanoemulsion and liposome using nRGD as therapeutic adjuvant for lung cancer therapy publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2017.09.041 contributor: fullname: Chen – volume: 20 start-page: 229 year: 2000 ident: 10.1016/j.nano.2021.102401_bb0220 article-title: Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma publication-title: Anticancer Res contributor: fullname: Grosios – volume: 68 start-page: 211 year: 2007 ident: 10.1016/j.nano.2021.102401_bb0280 article-title: Characterizing the tumor response to treatment with combretastatin A4 phosphate publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2006.12.051 contributor: fullname: Salmon – volume: 41 start-page: 799 year: 2005 ident: 10.1016/j.nano.2021.102401_bb0015 article-title: Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice publication-title: Eur J Cancer doi: 10.1016/j.ejca.2005.01.001 contributor: fullname: El-Emir – volume: 18 start-page: 3428 year: 2012 ident: 10.1016/j.nano.2021.102401_bb0305 article-title: Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-3376 contributor: fullname: Nathan – ident: 10.1016/j.nano.2021.102401_bb0150 doi: 10.1039/c2lc40634a – volume: 476 start-page: 241 year: 2014 ident: 10.1016/j.nano.2021.102401_bb0255 article-title: Construction of a two-in-one liposomal system (TWOLips) for tumor-targeted combination therapy publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2014.09.055 contributor: fullname: Su – volume: 60 start-page: 144 year: 2006 ident: 10.1016/j.nano.2021.102401_bb0260 article-title: A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies publication-title: PDA J Pharm Sci Technol contributor: fullname: Nallamothu – volume: 32 start-page: 1771 year: 2006 ident: 10.1016/j.nano.2021.102401_bb0120 article-title: Therapeutic effects of paclitaxel-containing ultrasound contrast agents publication-title: Ultrasound Med Biol doi: 10.1016/j.ultrasmedbio.2006.03.017 contributor: fullname: Tartis – volume: 51 start-page: 517 year: 1988 ident: 10.1016/j.nano.2021.102401_bb0035 article-title: Isolation, structure, synthesis, and antimitotic properties of combretastatins B-3 and B-4 from Combretum caffrum publication-title: J Nat Prod doi: 10.1021/np50057a011 contributor: fullname: Pettit – volume: 66 start-page: 2 year: 2014 ident: 10.1016/j.nano.2021.102401_bb0095 article-title: Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2013.11.009 contributor: fullname: Bertrand – volume: 77 start-page: 195 year: 2001 ident: 10.1016/j.nano.2021.102401_bb0180 article-title: Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues publication-title: Int J Radiat Biol doi: 10.1080/09553000010007695 contributor: fullname: Murata – volume: 74 start-page: 7003 year: 2014 ident: 10.1016/j.nano.2021.102401_bb0175 article-title: Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-14-0572 contributor: fullname: Kalra – volume: 4 start-page: 423 year: 2004 ident: 10.1016/j.nano.2021.102401_bb0210 article-title: The anti-angiogenic basis of metronomic chemotherapy publication-title: Nat Rev Cancer doi: 10.1038/nrc1369 contributor: fullname: Kerbel – volume: 2 start-page: 595 year: 2011 ident: 10.1016/j.nano.2021.102401_bb0300 article-title: Circulating endothelial progenitor cells in metronomic chemotherapy using irinotecan and/or bevacizumab for colon carcinoma: study of their clinical significance publication-title: Exp Ther Med doi: 10.3892/etm.2011.253 contributor: fullname: Murakami – volume: 7 start-page: E1 year: 2006 ident: 10.1016/j.nano.2021.102401_bb0240 article-title: A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation publication-title: AAPS PharmSciTech doi: 10.1208/pt070232 contributor: fullname: Nallamothu – volume: 2 start-page: 102 year: 2017 ident: 10.1016/j.nano.2021.102401_bb0045 article-title: Structural basis of cis- and trans-combretastatin binding to tubulin publication-title: Chem doi: 10.1016/j.chempr.2016.12.005 contributor: fullname: Gaspari – volume: 74 start-page: S86 year: 1996 ident: 10.1016/j.nano.2021.102401_bb0050 article-title: Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate publication-title: Br J Cancer contributor: fullname: Chaplin – volume: 14 start-page: 1789 year: 2019 ident: 10.1016/j.nano.2021.102401_bb0075 article-title: Liver-targeted liposomes for codelivery of curcumin and combretastatin A4 phosphate: preparation, characterization, and antitumor effects publication-title: Int J Nanomedicine doi: 10.2147/IJN.S188971 contributor: fullname: Jiang – volume: 10 start-page: 2667 year: 2013 ident: 10.1016/j.nano.2021.102401_bb0235 article-title: Irinotecan delivery by microbubble-assisted ultrasound: in vitro validation and a pilot preclinical study publication-title: Mol Pharm doi: 10.1021/mp400081b contributor: fullname: Escoffre – volume: 71 start-page: 76 year: 2006 ident: 10.1016/j.nano.2021.102401_bb0170 article-title: Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126 publication-title: Microvasc Res doi: 10.1016/j.mvr.2006.01.004 contributor: fullname: Cullis – volume: 62 start-page: 872 year: 2005 ident: 10.1016/j.nano.2021.102401_bb0020 article-title: Tumor physiologic response to combretastatin A4 phosphate assessed by MRI publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2005.03.009 contributor: fullname: Zhao – volume: 37 start-page: 63 year: 2011 ident: 10.1016/j.nano.2021.102401_bb0230 article-title: The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents publication-title: Cancer Tretment Rev doi: 10.1016/j.ctrv.2010.05.001 contributor: fullname: Siemann – volume: 13 start-page: 73 year: 2005 ident: 10.1016/j.nano.2021.102401_bb0080 article-title: Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugated and positively charged lipids publication-title: J Drug Target doi: 10.1080/10611860400011935 contributor: fullname: Wang – volume: 45 start-page: 209 year: 1989 ident: 10.1016/j.nano.2021.102401_bb0040 article-title: Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 publication-title: Experientia doi: 10.1007/BF01954881 contributor: fullname: Pettit – volume: 19 start-page: 233 year: 2009 ident: 10.1016/j.nano.2021.102401_bb0070 article-title: A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome publication-title: Thyroid doi: 10.1089/thy.2008.0321 contributor: fullname: Mooney – volume: 619 start-page: 8 year: 2009 ident: 10.1016/j.nano.2021.102401_bb0200 article-title: Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2009.08.020 contributor: fullname: Fioravanti – volume: 526 start-page: 547 year: 2017 ident: 10.1016/j.nano.2021.102401_bb0140 article-title: Evaluation of lipid-stabilised tripropionin nanodroplets as a delivery route for combretastatin A4 publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2017.05.009 contributor: fullname: Mico – volume: 40 start-page: 284 year: 2004 ident: 10.1016/j.nano.2021.102401_bb0295 article-title: Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence publication-title: Eur J Cancer doi: 10.1016/j.ejca.2003.09.006 contributor: fullname: Wildiers – volume: 5 start-page: 442 year: 2015 ident: 10.1016/j.nano.2021.102401_bb0005 article-title: Insoluble drug delivery strategies: review of recent advances and business prospects publication-title: Acta Pharm Sin B doi: 10.1016/j.apsb.2015.07.003 contributor: fullname: Kalepu – volume: 7 start-page: 216 year: 2007 ident: 10.1016/j.nano.2021.102401_bb0025 article-title: Dose-response relationship of ultrasound contrast agent in an in vivo murine melanoma model publication-title: Cancer Imaging doi: 10.1102/1470-7330.2007.0031 contributor: fullname: Seiler – volume: 81 start-page: 1318 year: 1999 ident: 10.1016/j.nano.2021.102401_bb0055 article-title: In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug publication-title: Br J Cancer doi: 10.1038/sj.bjc.6692174 contributor: fullname: Grosios – ident: 10.1016/j.nano.2021.102401_bb0145 – ident: 10.1016/j.nano.2021.102401_bb0215 doi: 10.1054/bjoc.2000.1361 – volume: 10 start-page: 10973 year: 2020 ident: 10.1016/j.nano.2021.102401_bb0130 article-title: Ultrasound-triggered therapeutic microbubbles enhance the efficacy of cytotoxic drugs by increasing circulation and tumor drug accumulation and limiting bioavailability and toxicity in normal tissues publication-title: Theranostics doi: 10.7150/thno.49670 contributor: fullname: Ingram – volume: 35 start-page: 2133 year: 2017 ident: 10.1016/j.nano.2021.102401_bb0115 article-title: Ultrasound molecular imaging with BR55 in patients with breast & ovarian lesions: first-in-human results publication-title: J Clin Oncol doi: 10.1200/JCO.2016.70.8594 contributor: fullname: Willmann – volume: 74 start-page: 467 year: 2010 ident: 10.1016/j.nano.2021.102401_bb0245 article-title: Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy : in vitro and in vivo studies publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2010.01.002 contributor: fullname: Zhang – volume: 29 start-page: 2902 year: 2012 ident: 10.1016/j.nano.2021.102401_bb0250 article-title: Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes publication-title: Pharm Res doi: 10.1007/s11095-012-0797-2 contributor: fullname: Dai – volume: 145 start-page: 393 year: 2017 ident: 10.1016/j.nano.2021.102401_bb0010 article-title: The development and use of vascular targeted therapy in ovarian cancer publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2017.01.031 contributor: fullname: Chase – volume: 34 start-page: 7181 year: 2013 ident: 10.1016/j.nano.2021.102401_bb0265 article-title: pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma publication-title: Biomaterials doi: 10.1016/j.biomaterials.2013.05.081 contributor: fullname: Wang – volume: 49 start-page: 39 year: 2009 ident: 10.1016/j.nano.2021.102401_bb0085 article-title: Acoustically active perfluorocarbon nanoemulsions as drug delivery carriers for camptothecin: drug release and cytotoxicity against cancer cells publication-title: Ultrasonics doi: 10.1016/j.ultras.2008.04.009 contributor: fullname: Fang – volume: 9 start-page: 1 year: 2019 ident: 10.1016/j.nano.2021.102401_bb0165 article-title: Development of orthotopic tumour models using ultrasound-guided intrahepatic injection publication-title: Sci Rep doi: 10.1038/s41598-019-46410-6 contributor: fullname: McVeigh – volume: 19 start-page: 566 year: 2020 ident: 10.1016/j.nano.2021.102401_bb0100 article-title: The entry of nanoparticles into solid tumours publication-title: Nat Mater doi: 10.1038/s41563-019-0566-2 contributor: fullname: Sindhwani – volume: 5 start-page: 2161 year: 2009 ident: 10.1016/j.nano.2021.102401_bb0110 article-title: Drug loaded microbubble design for ultrasound triggered delivery publication-title: Soft Matter doi: 10.1039/b823051j contributor: fullname: Lentacker – ident: 10.1016/j.nano.2021.102401_bb0060 doi: 10.1021/jm00010a011 – volume: 54 start-page: 1491 year: 2002 ident: 10.1016/j.nano.2021.102401_bb0190 article-title: The development of combretastatin A4 phosphate as a vascular targeting agent publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(02)03924-X contributor: fullname: Chaplin – volume: 12 start-page: 1 year: 2012 ident: 10.1016/j.nano.2021.102401_bb0290 article-title: Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments publication-title: BMC Cancer doi: 10.1186/1471-2407-12-522 contributor: fullname: Nguyen – ident: 10.1016/j.nano.2021.102401_bb0185 – volume: 12 start-page: 57 year: 2001 ident: 10.1016/j.nano.2021.102401_bb0275 article-title: Evaluation of combretastatin A-4 prodrug in a non-Hodgkin’s lymphoma xenograft model: preclinical efficacy publication-title: Anticancer Drugs doi: 10.1097/00001813-200101000-00008 contributor: fullname: Nabha – volume: 44 start-page: 840 year: 2018 ident: 10.1016/j.nano.2021.102401_bb0285 article-title: Quantitative evaluation of combretastatin A4 phosphate early efficacy in a tumor model with dynamic contrast-enhanced ultrasound publication-title: Ultrasound Med Biol doi: 10.1016/j.ultrasmedbio.2017.12.002 contributor: fullname: Zhang – volume: 38 start-page: 432 year: 2012 ident: 10.1016/j.nano.2021.102401_bb0160 article-title: High-frequency ultrasound for in vivo measurement of colon wall thickness in mice publication-title: Ultrasound Med Biol doi: 10.1016/j.ultrasmedbio.2011.12.011 contributor: fullname: Abdelrahman – volume: 7 start-page: 15444 year: 2016 ident: 10.1016/j.nano.2021.102401_bb0195 article-title: Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions publication-title: Oncotarget doi: 10.18632/oncotarget.6999 contributor: fullname: Liang – volume: 72 start-page: 49 year: 2014 ident: 10.1016/j.nano.2021.102401_bb0135 article-title: Understanding ultrasound induced sonoporation: definitions and underlying mechanisms publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2013.11.008 contributor: fullname: Lentacker – year: 2017 ident: 10.1016/j.nano.2021.102401_bb0155 contributor: fullname: Mico – volume: 7 start-page: 1052 year: 2001 ident: 10.1016/j.nano.2021.102401_bb0270 article-title: Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model publication-title: Clin Cancer Res contributor: fullname: Malcontenti-Wilson – volume: 115 start-page: 2992 year: 2005 ident: 10.1016/j.nano.2021.102401_bb0225 article-title: Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling publication-title: J Clin Invest doi: 10.1172/JCI24586 contributor: fullname: Vincent |
SSID | ssj0037009 |
Score | 2.4143267 |
Snippet | The hydrophobicity of a drug can be a major challenge in its development and prevents the clinical translation of highly potent anti-cancer agents. We have... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 102401 |
SubjectTerms | Animals Cell Line, Tumor Colorectal Neoplasms - drug therapy Colorectal Neoplasms - metabolism Colorectal Neoplasms - pathology Combretastatin A4 Humans Hydrophobic and Hydrophilic Interactions Lipid-Oil-Nanodroplets (LONDs) Lipids - chemistry Lipids - pharmacokinetics Lipids - pharmacology Mice Mice, Inbred BALB C Mice, Nude Microbubbles Nanostructures - chemistry Nanostructures - therapeutic use Stilbenes - chemistry Stilbenes - pharmacokinetics Stilbenes - pharmacology Targeting Ultrasonography Ultrasound trigger Xenograft Model Antitumor Assays |
Title | Targeted microbubbles carrying lipid-oil-nanodroplets for ultrasound-triggered delivery of the hydrophobic drug, combretastatin A4 |
URI | https://dx.doi.org/10.1016/j.nano.2021.102401 https://www.ncbi.nlm.nih.gov/pubmed/33894396 https://search.proquest.com/docview/2518230109 |
Volume | 36 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZ5QOklpM9s2i4q9Naqa9laeX1clobtI6G0CeQmJFlKHBx78dqHXHrIL--MLRcKbQ892lhI1oxmvmG-0RDyRkY5qIb1LDWgweAxNNNxbhkYSexqJW2SYjXy6ZlcX4hPl_PLHbIaa2GQVhls_2DTe2sd3szCbs42RTH7jpeLgfqImPdpyXSX7IM7wlzt_vLj5_XZaJCTNOqZHvg9wwGhdmageVW6whrAmOMlBiL0hvmDf_ob_uz90MkhOQgAki6HNT4iO656TB6chhT5E3J_3nO7XU5vkWtnOmNKt6VWNw1WNNGy2BQ5q4uS4ZryBgnk7ZYCdqVd2TZ6i32WWAtB-xW28aS5K5G6cUdrTwEs0us7HHNdm8LSvOmu3lHYOoOsRaxNKiq6FE_JxcmH89WahUYLzMIRbhkXTmTgprCBaOw0YBqbGs8X0vg0TYT1UkPkYWOdepkDJNQLmVjvuMwg2DCRSZ6Rvaqu3BGh1i0ym_jIC2-EnWeax9wAJpZGQxjOFxPydtxetRnu01Aj0exG4Y8rFIYahDEh81EC6jetUGDw_znu9SguBccFcyC6cnW3VQDnMLXIo2xCng9y_LUOiNYzwGfy-D9nfUEe4tNAD3xJ9tqmc68AsrRmSnbf_-BTUMzVty9fp0FBfwJLTOy1 |
link.rule.ids | 314,780,784,4502,24116,27924,27925,45585,45679 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIkEviDfL00jcwGyceJ3NsaqoFuj2wlbqzbIduw0KySqbHHrpgV_OTB6VkIAD18RWnJnxzGfNNx6AdyrK0TRc4KlFC8aIYbiJc8fRSVJXK-WSlKqR16dqdSa_nC_O9-BoqoUhWuXo-wef3nvr8cl8lOZ8WxTzb3S5GJqPjEWflkxvwW25QPSLRv3x-obnkaRRz_Og0ZyGj5UzA8mrMhVVAMaCrjCQY2eYP0Snv6HPPgod34d7I3xkh8MKH8Cerx7CnfWYIH8EPzc9s9vn7Acx7Wxnbel3zJmmoXomVhbbIud1UXJaU94QfbzdMUSurCvbxuyoyxJv8ch-QU08We5LIm5csTowhIrs8ormXNa2cCxvuosPDAVnibNIlUlFxQ7lYzg7_rQ5WvGxzQJ3uIFbLqSXGQYpah8ae4OIxqU2iKWyIU0T6YIyeO5wsUmDyhEQmqVKXPBCZShsG9nkCexXdeWfAXN-mbkkREEGK90iMyIWFhGxsgYP4WI5g_eTePV2uE1DTzSz75p-XJMy9KCMGSwmDejfbEKju__nvLeTujRuFsqAmMrX3U4jmKPEooiyGTwd9HizDjyrZ4jO1PP__OobuLvarE_0yefTry_ggN4MRMGXsN82nX-F4KW1r3vj_AUOr-v5 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeted+microbubbles+carrying+lipid-oil-nanodroplets+for+ultrasound-triggered+delivery+of+the+hydrophobic+drug%2C+combretastatin+A4&rft.jtitle=Nanomedicine&rft.au=Charalambous%2C+Antonia&rft.au=Mico%2C+Victoria&rft.au=McVeigh%2C+Laura+E.&rft.au=Marston%2C+Gemma&rft.date=2021-08-01&rft.issn=1549-9634&rft.volume=36&rft.spage=102401&rft_id=info:doi/10.1016%2Fj.nano.2021.102401&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_nano_2021_102401 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1549-9634&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1549-9634&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1549-9634&client=summon |